TEMPEST THERAPEUTICS, INC.

Analyst Reco. Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
3.54 ^USD	-2.21%		+1.72%	-19.55%

04-09	Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	CI
04-04	Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	03-14	MT
HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	11/10/23	MT
Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	23/03/23	MT
Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target	15/09/22	MT
HC Wainwright Adjusts Tempest Therapeutics Price Target to $35 From $51, Maintains Buy Rating	13/05/22	MT
Piper Sandler Adjusts Price Target on Tempest Therapeutics to $20 From $23, Reiterates Overweight Rating	28/04/22	MT
TEMPEST THERAPEUTICS : William Blair Initiates Tempest Therapeutics at Outperform Rating	21/10/21	MT
TEMPEST THERAPEUTICS : HC Wainwright Starts Tempest Therapeutics at Buy With $51 Price Target	13/07/21	MT
TEMPEST THERAPEUTICS : Piper Sandler Starts Tempest Therapeutics at Overweight With $23 Price Target	06/07/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer